{"id":"sorafenib-standard-dosing-regimen","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Hand-foot skin reaction"},{"rate":"25-35","effect":"Diarrhea"},{"rate":"20-30","effect":"Rash"},{"rate":"15-25","effect":"Fatigue"},{"rate":"15-25","effect":"Hypertension"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Alopecia"},{"rate":"5-15","effect":"Bleeding"}]},"_chembl":{"chemblId":"CHEMBL1200485","moleculeType":"Small molecule","molecularWeight":"637.04"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sorafenib inhibits multiple targets including BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, and c-KIT. By blocking these kinases, it suppresses both tumor cell growth directly and the formation of new blood vessels that feed tumors (angiogenesis), thereby limiting tumor progression.","oneSentence":"Sorafenib is a multi-kinase inhibitor that blocks several receptor tyrosine kinases involved in tumor cell proliferation and angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:46.920Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced renal cell carcinoma"},{"name":"Unresectable hepatocellular carcinoma"},{"name":"Radioactive iodine-refractory differentiated thyroid cancer"}]},"trialDetails":[{"nctId":"NCT01265576","phase":"PHASE2","title":"Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)","status":"UNKNOWN","sponsor":"Vicus Therapeutics","startDate":"2010-12","conditions":"HCC","enrollment":20},{"nctId":"NCT01203787","phase":"PHASE4","title":"Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"University of Florida","startDate":"2010-12","conditions":"Hepatocellular Carcinoma","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nexavar(Bay43-9006)"],"phase":"marketed","status":"active","brandName":"Sorafenib Standard Dosing Regimen","genericName":"Sorafenib Standard Dosing Regimen","companyName":"University of Florida","companyId":"university-of-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sorafenib is a multi-kinase inhibitor that blocks several receptor tyrosine kinases involved in tumor cell proliferation and angiogenesis. Used for Advanced renal cell carcinoma, Unresectable hepatocellular carcinoma, Radioactive iodine-refractory differentiated thyroid cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}